A Study of Atezolizumab in Participants With Programmed Death-Ligand 1 (PD-L1) Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) [FIR]

Inclusion Criteria:

   - Stage IIIB (not eligible for definitive chemoradiotherapy), Stage IV, or recurrent
   NSCLC

   - PDL1-positive status as determined by an immunohistochemistry assay performed by a
   central laboratory. A positive result in chemotherapy, chemoradiation of the tumor
   sample biopsy will satisfy the eligibility criterion

   - Eastern Cooperative Oncology group Performance Status of 0 or 1

   - Life expectancy greater than or equal to 12 weeks

   - Measurable disease, as defined by Response Evaluation Criteria in Solid Tumors Version
   1.1

   - Adequate hematologic and end organ function

Exclusion Criteria:

   - Any approved anti-cancer therapy, including chemotherapy, or hormonal therapy within 3
   weeks prior to initiation of study treatment; the following exceptions are allowed.
   Hormone-replacement therapy or oral contraceptives, and tyrosine kinase inhibitors
   approved for treatment of NSCLC discontinued greater than 7 days prior to Cycle 1 Day
   1

   - Treatment with any other investigational agent or participation in another clinical
   trial with therapeutic intent within 28 days prior to enrollment

   - Known central nervous system disease, including treated brain metastases in the
   following participants:

      1. who will not receive prior chemotherapy for advanced disease

      2. who progress during or following a prior-platinum based chemotherapy regimen for
      advanced disease (referred as 2L+ participants)

   - Participants with a history of treated asymptomatic brain metastases are allowed in
   the 2L+ participants and previously treated for brain metastases.

   - Leptomeningeal disease

   - Uncontrolled tumor-related pain

   - Uncontrolled hypercalcemia